Shareholders Equity (Quarterly) Chart

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
September 30, 2026 18.85M
June 30, 2026 7.937M
March 31, 2026 -1.437M
December 31, 2025 1.636M
September 30, 2025 3.816M
June 30, 2025 1.834M
March 31, 2025 8.904M
December 31, 2024 -11.31M
September 30, 2024 -18.99M
June 30, 2024 -1.652M
March 31, 2024 4.87M
December 31, 2023 11.37M
September 30, 2023 13.29M
June 30, 2023 23.56M
Date Value
March 31, 2023 39.67M
December 31, 2022 8.915M
September 30, 2022 50.21M
June 30, 2022
March 31, 2022 67.20M
December 31, 2021 81.51M
September 30, 2021 64.51M
June 30, 2021 77.19M
March 31, 2021 92.44M
December 31, 2020 -90.45M
September 30, 2020 -63.19M
June 30, 2020
March 31, 2020
December 31, 2019 -18.59M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. 67.06M
Armata Pharmaceuticals, Inc. -174.13M
Voyager Therapeutics, Inc. 135.11M
Black Diamond Therapeutics, Inc. 88.08M
Invivyd, Inc. 150.48M

Shareholders Equity (Quarterly) Related Metrics